---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-138242"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2024-12-19T23:59:59+00:00"
generated_at: "2026-05-29T01:26:22.194613+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Assembly Bio receives $10M from Gilead, Gilead buys 940,499 shares at $21.37

## Summary
- Gilead pays $10M upfront payment creditable against future collaboration obligations.
- Opt-in fees for ABI-6250 restructured; total aggregate payments unchanged.
- Gilead purchases 940,499 shares at $21.37/share, a 35% premium to 30-day VWAP.
- Amendment redefines Phase 1b clinical trial and Triggering Clinical Trial for certain programs.
- Additional Funding Payment of $10M due within [***] days; use restricted per Section 15.5(a).

## SEC filing metadata
- accession: 0000950170-24-138242
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2024-12-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000095017024138242/0000950170-24-138242-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000095017024138242/asmb-20241219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-138242
- JSON: https://secwatch.observer/filing/0000950170-24-138242.json
- Plain text: https://secwatch.observer/filing/0000950170-24-138242.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.